	Application No.	Applicant(s)
Notice of Allowability	09/751,797	DUMOUTIER ET AL.
	Examiner	Art Unit
	Phillip Gambel	1644
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject to	oplication. If not included n will be mailed in due course. THIS
1. This communication is responsive to <u>12/1/05; 3/30/06</u> .		
2. The allowed claim(s) is/are 53-56 renumbered 1-4.		
 Acknowledgment is made of a claim for foreign priority ureal. All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have international Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	been received. been received in Application No	
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give	itted. Note the attached EXAMINER es reason(s) why the oath or declara	R'S AMENDMENT or NOTICE OF ation is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on the drawing he header according to 37 CFR 1.121	ings in the front (not the back) of (d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	·	·
1. Notice of References Cited (PTO-892)	_	Patent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 Interview Summary Paper No./Mail Da 	
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 	8), 7. ☐ Examiner's Amend	ment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Statem	ent of Reasons for Allowance
	9. Other	

Application/Control Number: 09/751,797

Art Unit: 1644

DETAILED ACTION

 Applicant's amendment, filed 12/1/05, has been entered. Claims 1-52 have been canceled.

Claims 53-56 are pending.

2. Applicant's Status Inquiry, filed 3/30/06, is acknowledged.

This Office Action should serve in response to applicant's After Final Amendment and Status Inquiry.

The examiner apologizes for any inconvenience to applicant in this matter.

REASONS FOR ALLOWANCE

3. The following is an Examiner's Statement of Reasons for Allowance:

As indicated in the previously, the instant claims appear to be free of the prior art. It does not appear that the prior art teaches or suggests the particular isolated nucleic acids claimed. Accordingly, the instant claims appear to be allowable.

4. The non-statutory double patenting rejection, whether of the obvious-type or non-obvious-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. *In re Thorington,* 418 F.2d 528, 163 USPQ 644 (CCPA 1969); *In re Vogel,* 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Van Ornam,* 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Longi,* 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and *In re Goodman,* 29 USPQ2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321 (b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78 (d).

Effective January 1, 1994, a registered attorney or agent of record may sign a Terminal Disclaimer. A Terminal Disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 53-56 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 50 of copending application USSN 10/627,723. Although the conflicting claims are not identical, they are not patentably distinct from each other because each composition is drawn to the same or nearly the same nucleic acids encoding a T cell inducible factor comprising SEQ ID NO: 24. Therefore, the instant or copending claims appear to either anticipate or render obvious one another.

This is a *provisional* obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Art Unit: 1644

Given that a provisional double patenting rejection over copending USSN 10/627,723 would be the only rejection remaining in this application; such a provisional obvious double patenting is withdrawn to permit this application to issue. See MPEP 804.

- 5. Any comments considered necessary by applicant must be submitted no later than the payment of the issue Fee and, to avoid processing delays, should preferably **accompany** the Issue Fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (571) 272-0844. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Phillip Gambel, Ph.D., J.D. Primary Examiner Technology Center 1600

April 3, 2006

Decoupe Imper